Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
---|---|---|---|---|---|
![]() | AB INBEV | - | 9 | -0,23 % | |
![]() | UCB | - | 8 | -1,11 % | |
![]() | GALAPAGOS NV | - | 3 | +0,05 % | |
![]() | AGEAS | - | 1 | +0,20 % | |
![]() | SOLVAY | - | 1 | -1,59 % | |
![]() | PROXIMUS | - | 1 | -0,22 % | |
![]() | ACKERMANS & VAN HAAREN | - | 1 | -0,56 % | |
![]() | AEDIFICA | - | 1 | +0,38 % | |
ARGENX | - | 1 | +0,11 % | ||
![]() | BARCO | - | - | -0,97 % |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Aedifica NV/SA: Result of the optional dividend | 268 | GlobeNewswire (Europe) | Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding the result of the 2022 optional... ► Artikel lesen | |
Do | ClearPoint Neuro, Inc.: ClearPoint Neuro und UCB unterzeichnen Lizenzvereinbarung für die Verabreichung von Gentherapeutika | 284 | GlobeNewswire (Deutschland) | SOLANA BEACH, Kalifornien, May 25, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT), ein weltweit tätiges Unternehmen, das Neuronavigationssysteme für die Durchführung von Eingriffen am... ► Artikel lesen | |
Do | Ackermans & van Haaren: Handelsaussetzung - 25.05.2023 | 2 | Wiener Börse | ||
Do | Solvay S.A.: Participation notification by Blackrock Inc. | 234 | GlobeNewswire (Europe) | Participation notification by Blackrock Inc.
Brussels, 25 May 2023, 08:30 CET - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York... ► Artikel lesen | |
Mi | ClearPoint Neuro enters drug delivery licensing deal with UCB | 1 | MassDevice | ||
Mi | Veeva in deal with UCB to leverage digital tools to help patient trial experiences | 1 | FierceBiotech | ||
Mi | UCB inks license agreement with ClearPoint Neuro for epilepsy and neurodegeneration gene therapy research | 1 | Endpoints News | ||
Mi | Buy or Sell Anheuser-Busch Stock? Here's Where It May Find Support | 13 | The Street | ||
Mi | Anheuser-Busch InBev Unusual Options Activity For May 24 | 6 | Benzinga.com | ||
Mi | ClearPoint Neuro in pact with UCB for gene therapy delivery | 1 | Seeking Alpha | ||
Mi | Should You Buy the Dip in Anheuser-Busch Stock? | 8 | Baystreet.ca | ||
Mi | ClearPoint Neuro, Inc.: ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery | 384 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced... ► Artikel lesen | |
Mi | BARCLAYS stuft AB Inbev auf 'Overweight' | 490 | dpa-AFX-Analyser | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für AB Inbev angesichts eines US-Boykott-Aufrufs für die Biermarke "Bud Light" von 73 auf 65 Euro gesenkt, die Einstufung... ► Artikel lesen | |
Di | Anheuser-Busch Follows Coke In Killing Popular Brands | 8 | The Street | ||
Di | Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis | 339 | GlobeNewswire (Europe) | GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases... ► Artikel lesen | |
Di | Veeva in pact with Belgian biopharma UCB for tech-driven clinical trials | 3 | Seeking Alpha | ||
Di | GALAPAGOS NV - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
Di | JPMORGAN stuft AB Inbev auf 'Overweight' | 635 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für AB Inbev auf "Overweight" mit einem Kursziel von 70 Euro belassen. Dass sich der Kurs der Brauerei-Aktie trotz eines starken... ► Artikel lesen | |
Di | Veeva Systems: UCB and Veeva Collaborate to Advance the Patient Experience in Clinical Trials | 278 | PR Newswire | Companies collaborate to set a new standard for patient-centric digital clinical trials
BRUSSELS and PLEASANTON, Calif., May 23, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and... ► Artikel lesen | |
Mo | Human Rights Campaign 'suspends AB InBev's "top LGBTQ+" rating' | 10 | Just Drinks |